Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological response (pCR) exhibited superior recurrence-free su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2020-11, Vol.31 (11), p.1569-1579
Hauptverfasser:	Tetzlaff, M.T., Adhikari, C., Lo, S., Rawson, R.V., Amaria, R.N., Menzies, A.M., Wilmott, J.S., Ferguson, P.M., Ross, M.I., Spillane, A.J., Vu, K.A., Ma, J., Ning, J., Haydu, L.E., Saw, R.P.M., Wargo, J.A., Tawbi, H.A., Gershenwald, J.E., Long, G.V., Davies, M.A., Scolyer, R.A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease-Free Survival Humans melanoma Melanoma - drug therapy Melanoma - genetics neoadjuvant Neoadjuvant Therapy Neoplasm Recurrence, Local Neoplasms, Second Primary pathology Skin Neoplasms - drug therapy Skin Neoplasms - genetics therapy treatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!